Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: The role of GPI signal sequence

Vaccine

Volumn 25, Issue 8, 2007, Pages 1426-1436

  Ophorst, Olga J A E ^a,b   Radošević, Katarina ^a   Ouwehand, Krista ^a   van Beem, Wouter ^a   Mintardjo, Ratna ^a   Sijtsma, Jeroen ^a   Kaspers, Jorn ^a   Companjen, Arjen ^a   Holterman, Lennart ^a   Goudsmit, Jaap ^a,b   Havenga, Menzo J E ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adenovirus vaccines; Circumsporozoite protein; Immunogenicity; Malaria

Indexed keywords

ADENOVIRUS VECTOR; CIRCUMSPOROZOITE PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL; LIVE VACCINE; MALARIA VACCINE; PROTEIN ANTIBODY; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOGENICITY; MORTALITY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; B-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; GENE DELETION; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; MALARIA VACCINES; MICE; MICE, INBRED CBA; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; PROTEIN SORTING SIGNALS; PROTOZOAN PROTEINS; T-LYMPHOCYTES;

EID: 33846068020     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.10.050     Document Type: Article

References (53)

1. Ophorst O.J., Radosevic K., Havenga M.J., Pau M.G., Holterman L., Berkhout B., et al. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 74 (2006) 313-320
2. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172 (2004) 6290-6297
3. Maeda K., West K., Hayasaka D., Ennis F.A., and Terajima M. Recombinant adenovirus vector vaccine induces stronger cytotoxic T-cell responses than recombinant vaccinia virus vector, plasmid DNA, or a combination of these. Viral Immunol 18 (2005) 657-667
4. Nanda A., Lynch D.M., Goudsmit J., Lemckert A.A., Ewald B.A., Sumida S.M., et al. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. Virol 79 (2005) 14161-14168
5. Lemckert A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 15 (2005) 9694-9701
6. Barratt-Boyes S.M., Soloff A.C., Gao W., Nwanegbo E., Liu X., Rajakumar P.A., et al. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors. J Gen Virol 87 (2006) 139-149
7. Sedegah M., Sim B.K., Mason C., Nutman T., Malik A., Roberts C., et al. Naturally acquired CD8+ cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. J Immunol 149 (1992) 966-971
8. Krzych U., and Schwenk J. The dissection of CD8 T cells during liver-stage infection. Curr Top Microbiol Immunol 297 (2005) 1-24
9. Hafalla J.C., Cockburn I.A., and Zavala F. Protective and pathogenic roles of CD8+ T cells during malaria infection. Parasite Immunol 28 (2006) 15-24
10. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.Y., Roederer M., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424 (2003) 681-684
11. Shiver J.W., and Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55 (2004) 355-372
12. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A., et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79 (2005) 6516-6522
13. Herrington D., Davis J., Nardin E., Beier M., Cortese J., Eddy H., et al. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 45 (1991) 539-547
14. Nardin E., Munesinghe Y.D., Moreno A., Clavijo P., Calle M.C., Edelman R., et al. T cell responses to repeat and non-repeat regions of the circumsporozoite protein detected in volunteers immunized with Plasmodium falciparum sporozoites. Mem Inst Oswaldo Cruz 87 Suppl. 3 (1992) 223-227
15. Egan J.E., Hoffman S.L., Haynes J.D., Sadoff J.C., Schneider I., Grau M.R., et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 49 (1993) 166-173
16. Hoffman S.L., Wistar Jr. R., Ballou W.R., Hollingdale M.R., Wirtz R.A., Schneider I., et al. Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. N Engl J Med 315 (1986) 601-606
17. Good M.F., Pombo D., Quakyi I.A., Riley E.M., Houghten R.A., Menon A., et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci USA 85 February (1988) 1199-1203
18. Shi Y.P., Udhayakumar V., Alpers M.P., Povoa M.M., Oloo A.J., Ruebush II T.K., et al. Natural antibody responses against the non-repeat-sequence-based B-cell epitopes of the Plasmodium falciparum circumsporozoite protein. Infect Immun 61 (1993) 2425-2433
19. Calle J.M., Nardin E.H., Clavijo P., Boudin C., Stuber D., Takacs B., et al. Recognition of different domains of the Plasmodium falciparum CS protein by the sera of naturally infected individuals compared with those of sporozoite-immunized volunteers. J Immunol 149 (1992) 2695-2701
20. Lopez J.A., Roggero M.A., Duombo O., Gonzalez J.M., Tolle R., Koita O., et al. Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors. Am J Trop Med Hyg 55 (1996) 424-429
21. Udhayakumar V., Ongecha J.M., Shi Y.P., Aidoo M., Orago A.S., Oloo A.J., et al. Cytotoxic T cell reactivity and HLA-B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ CTL epitope in naturally exposed Kenyan adults. Eur J Immunol 27 (1997) 1952-1957
22. Avila S.L., Goldberg A.C., Arruk V.G., Marin M.L., Guilherme L., Kalil J., et al. Immune responses to multiple antigen peptides containing T and B epitopes from Plasmodium falciparum circumsporozoite protein of Brazilian individuals naturally exposed to malaria. Parasite Immunol 23 (2001) 103-108
23. Reece W.H., Pinder M., Gothard P.K., Milligan P., Bojang K., Doherty T., et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 10 (2004) 406-410
24. Rodrigues E.G., Zavala F., Eichinger D., Wilson J.M., and Tsuji M. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol 158 (1997) 1268-1274
25. Scheiblhofer S., Chen D., Weiss R., Khan F., Mostböck S., Fegeding K., et al. Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP-specific Th2 type immune responses and improves protection against malaria infection. Eur J Immunol 31 (2001) 692-698
26. Bruna-Romero O., Rocha C.D., Tsuji M., and Gazzinelli R.T. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine 22 (2004) 3575-3584
27. Amthauer R., Kodukula K., Gerber L., and Udenfriend S. Evidence that the putative COOH-terminal signal transamidase involved in glycosylphosphatidylinositol protein synthesis is present in the endoplasmic reticulum. Proc Natl Acad Sci USA 90 (1993) 3973-3977
28. Spurway T.D., Dalley J.A., High S., and Bulleid N.J. Early events in glycosylphosphatidyl-inositol anchor addition. Substrate proteins associate with the transamidase subunit gpi8p. J Biol Chem 276 (2001) 15975-15982
29. Eisenhaber B., Maurer-Stroh S., Novatchkova M., Schneider G., and Eisenhaber F. Enzymes and auxiliary factors for GPI lipid anchor biosynthesis and post-translational transfer to proteins. Bioessays 25 (2003) 367-385
30. Moran P., and Caras I.W. Requirements for glycosylphosphatidylinositol attachment are similar but not identical in mammalian cells and parasitic protozoa. J Cell Biol 125 2 (1994) 333-343
31. Udenfriend S., and Kodukula K. How glycosylphosphatidylinositol-anchored membrane proteins are made. Annu Rev Biochem 64 (1995) 563-591
32. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77 (2003) 8263-8271
33. de Ruijter A.J., Kemp S., Kramer G., Meinsma R.J., Kaufmann J.O., Caron H.N., et al. The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells. Biochem Pharmacol 1 (2004) 1279-1288
34. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66 (1975) 188-193
35. Nardin E.H., Calvo-Calle J.M., Oliveira G.A., Nussenzweig R.S., Schneider M., Tiercy J.M., et al. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J Immunol 166 (2001) 481-489
36. Fallaux F.J., Bout A., van der Velde I., van den Wollenberg D.J., Hehir K.M., Keegan J., et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9 13 (1998) 1909-1917
37. Bloland P.B., Boriga D.A., Ruebush T.K., McCormick J.B., Roberts J.M., Oloo A.J., et al. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission II. Descriptive epidemiology of malaria infection and disease among children. Am J Trop Med Hyg 60 (1999) 641
38. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 (2004) 1411-1420
39. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Aide P., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 (2005) 2012-2018
40. Wang D., Schmaljohn A.L., Raja N.U., Trubey C.M., Juompan L.Y., Luo M., et al. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine 24 (2006) 2975-2986
41. Capone S., Meola A., Ercole B.B., Vitelli A., Pezzanera M., Ruggeri L., et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 80 (2006) 1688-1699
42. Kostense S., Koudstaal W., Sprangers M., Weverling G.J., Penders G., Helmus N., et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18 (2004) 1213-1216
43. Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11 (2004) 351
44. Seshidhar R., Ganesh S., Limbach M.P., Brann T., Pinkstaff A., Kaloss M., et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 311 (2003) 384-393
45. Mei Y.F., Segerman A., Lindman K., Hornsten P., Wahlin A., and Wadell G. Human hematopoietic (CD34+) stem cells possess high-affinity receptors for adenovirus type 11p. Virology 328 (2004) 198-207
46. Holterman L., Vogels R., van der Vlugt R., Sieuwerts M., Grimbergen J., Kaspers J., et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol 78 (2004) 13207-13215
47. ®cells, tropism, and immunogenicity. J Gen Virol 87 (2006) 2891-2899
48. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441 (2006) 239-243
49. Moran P., and Caras I.W. A nonfunctional sequence converted to a signal for glycophosphatidylinositol membrane anchor attachment. J Cell Biol 115 (1991) 329-336
50. Moran P., and Caras I.W. Proteins containing an uncleaved signal for glycophosphatidyl-inositol membrane anchor attachment are retained in a post-ER compartment. J Cell Biol 119 (1992) 763-772
51. Field M.C., Moran P., Li W., Keller G.A., and Caras I.W. Retention and degradation of proteins containing an uncleaved glycosylphosphatidylinositol signal. J Biol Chem 269 (1994) 10830-10837
52. Bohme U., and Cross G.A. Mutational analysis of the variant surface glycoprotein GPI-anchor signal sequence in Trypanosoma brucei. J Cell Sci 115 (2002) 805-816
53. Delahunty M.D., Stafford F.J., Yuan L.C., Shaz D., and Bonifacino J.S. Uncleaved signals for glycosylphosphatidylinositol anchoring cause retention of precursor proteins in the endoplasmic reticulum. J Biol Chem 268 (1993) 12017-12027